HK Stock Market Move | GENSCRIPT BIO (01548) once fell more than 10%, Legendary Biology's lymphoma therapy research has achieved an objective relief rate of 100%.

GenScript BIO (01548) once fell by more than 10%, as of the time of writing, it has fallen by 8.37% to HKD 11.93, with a turnover of 295 million Hong Kong dollars. On the news front, the joint venture company of GenScript BIO, Legend Biotech, recently announced the first clinical concept validation data for its in-house CD19/CD20 dual-target CAR-T cell therapy LB2501 for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) patients. The study results were presented at the latest breakthrough session at the 2026 European Hematology Association (EHA) Annual Meeting. In an ongoing Phase I study, relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) patients who received a single infusion achieved 100% ORR and 83.3% CR rate at the second dose level (DL2). As of the data cut-off, all responses are still ongoing. LB2501 also demonstrated good safety features, with no reported dose-limiting toxicity (DLT), serious adverse events (SAE), immune effector cell-associated neurotoxicity syndrome (ICANS), or death events.